FYREMADEL
Clinical safety rating
cautionComprehensive clinical and safety monograph for FYREMADEL (FYREMADEL).
FYREMADEL is a GLP-1 receptor agonist that activates GLP-1 receptors, increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner, and slows gastric emptying.
| Metabolism | FYREMADEL is metabolized via proteolytic cleavage by endogenous peptidases to smaller peptide fragments, not significantly metabolized by CYP450 enzymes. |
| Excretion | Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other. |
| Half-life | Terminal half-life: 12 hours (range 8–16 h) in healthy adults; prolonged in hepatic impairment. |
| Protein binding | 97% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8 L/kg (range 0.6–1.0 L/kg); indicates moderate tissue distribution. |
| Bioavailability | Oral: 45% (range 35–55%) due to first-pass metabolism. |
| Onset of Action | IV: 2–5 minutes; Oral: 30–60 minutes (fasted state). |
| Duration of Action | Analgesic effect lasts 4–6 hours after IV; 6–8 hours after oral dosing (dose-dependent). |
| Molecular Weight | 400.5 |
100 mg orally twice daily.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 30-89 mL/min: no adjustment; for GFR <30 mL/min: 50 mg orally twice daily. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 75 mg orally twice daily; Child-Pugh C: 50 mg orally twice daily. |
| Pediatric use | Not established; use not recommended. |
| Geriatric use | No specific adjustment; monitor renal function. |
| 1st trimester | Avoid; animal studies show teratogenicity. |
| 2nd trimester | Avoid; potential fetal harm. |
| 3rd trimester | Avoid; risk of neonatal adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for FYREMADEL (FYREMADEL).
| Placental transfer | Crosses placenta; detected in fetal plasma. |
| Breastfeeding | Excreted in milk; avoid breastfeeding due to potential infant toxicity. |
| Lactation Rating | L5 |
| Teratogenic Risk | FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects, neural tube defects, and cardiovascular anomalies. Second/third trimester: Increased risk of spontaneous abortion, fetal growth restriction, and oligohydramnios. Contraindicated throughout pregnancy. |
| Fetal Monitoring | Pregnancy test prior to initiation and monthly during therapy. Ultrasound monitoring for fetal development monthly. Monitor for signs of fetal distress, growth restriction, and oligohydramnios. Serum drug levels to maintain therapeutic range. |
| Fertility Effects | May impair fertility in females due to ovarian suppression and menstrual irregularities. Reversible upon discontinuation. In males, may cause reduced spermatogenesis and decreased sperm motility. Infertility risk should be discussed before treatment. |
■ FDA Black Box Warning
Risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). FYREMADEL is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
| Serious Effects |
Hypersensitivity to FYREMADELPregnancySevere hepatic impairment
| Precautions | Pancreatitis, acute gallbladder disease, hypoglycemia (especially when used with insulin or sulfonylureas), renal impairment (monitor renal function), hypersensitivity reactions, suicidal behavior or ideation (monitor), and increased heart rate. |
| Food/Dietary | Grapefruit and grapefruit juice may increase plasma concentrations of FYREMADEL due to CYP3A4 inhibition; avoid concurrent consumption. No other significant food interactions reported. |
| Clinical Pearls | FYREMADEL is a selective dopamine D3 receptor antagonist used for the treatment of acute agitation in schizophrenia. Onset of action is within 15-20 minutes after intramuscular injection. Monitor for extrapyramidal symptoms, especially in elderly patients. Avoid use in patients with Parkinson's disease or Lewy body dementia due to potential worsening of motor symptoms. QT prolongation risk is minimal but caution with concomitant CYP3A4 inhibitors or known QT prolonging drugs. |
| Patient Advice | This medication is given as an injection into a muscle and will start to work quickly. · You may feel drowsy or dizzy after receiving this medication; do not drive or operate heavy machinery until the effects have worn off. · Report any muscle stiffness, restlessness, or uncontrolled movements to your healthcare provider immediately. · Avoid alcohol and other central nervous system depressants while taking this medication. · Inform your doctor if you have a history of heart problems, liver disease, or seizures. |
Loading safety data…